Literature DB >> 26983700

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Pekka Peroja1, Kirsi-Maria Haapasaari2, Susanna Mannisto3, Ilkka Miinalainen4, Petri Koivunen5, Sirpa Leppä3, Marja-Liisa Karjalainen-Lindsberg6, Milla Elvi Linnea Kuusisto7, Taina Turpeenniemi-Hujanen7, Outi Kuittinen7, Peeter Karihtala7.   

Abstract

Redox state-regulating enzymes may have roles in chemoresistance and also in lymphomagenesis, but there have been only a limited number of studies on this topic in lymphomas. Our aim was to assess expression of the redox state-regulating enzymes peroxiredoxins (Prxs) I-VI and thioredoxin (Trx) and the oxidative stress marker nitrotyrosine in follicular lymphomas (FLs). We immunohistochemically assessed Prxs I-VI, Trx and nitrotyrosine in a cohort of 76 histologically confirmed, untreated FLs. We also studied the localisation of Prxs I, II, III, V and VI by means of immunoelectron microscopy (IEM). Immunohistochemistry results were correlated with disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS) and clinical prognostic factors. When all Prx expression intensities were grouped as a single variable, we discovered that high total Prx intensity correlated with favourable DSS (p = 0.024) and OS (p = 0.035) but not with PFS. No deaths due to lymphoma were recorded amongst patients with high total Prx expression during the median follow-up period of 7.6 years. IEM results were in line with earlier ones demonstrating wide subcellular localisation of Prx isoenzymes. In conclusion, our results demonstrate an association between high total Prx expression and prolonged survival and suggest that Prxs may have a protective role in FL that cannot be compensated by other antioxidant mechanisms.

Entities:  

Keywords:  Follicular lymphoma; Immunohistochemistry; Oxidative stress; Peroxiredoxins; Prognostic factors; Thioredoxin

Mesh:

Substances:

Year:  2016        PMID: 26983700     DOI: 10.1007/s00428-016-1920-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.

Authors:  Milla Elvi Linnea Kuusisto; Kirsi-Maria Haapasaari; Taina Turpeenniemi-Hujanen; Esa Jantunen; Ylermi Soini; Pekka Peroja; Risto Bloigu; Peeter Karihtala; Outi Kuittinen
Journal:  J Clin Pathol       Date:  2015-05-02       Impact factor: 3.411

2.  A new method of preparing gold probes for multiple-labeling cytochemistry.

Authors:  J W Slot; H J Geuze
Journal:  Eur J Cell Biol       Date:  1985-07       Impact factor: 4.492

3.  Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.

Authors:  Vuokko L Kinnula; S Lehtonen; R Sormunen; R Kaarteenaho-Wiik; S W Kang; S G Rhee; Y Soini
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

4.  Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress.

Authors:  Weidong Lu; Zhongxue Fu; Hao Wang; Jihong Feng; Jinlai Wei; Jinbao Guo
Journal:  Mol Cell Biochem       Date:  2013-11-15       Impact factor: 3.396

5.  Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation.

Authors:  Ana Paula Dias Demasi; Elizabeth Ferreira Martinez; Marcelo Henrique Napimoga; Leandro Lopes Freitas; Jose Vassallo; Adriana Silva Santos Duarte; Andresa Borges Soares; Ney Soares Araujo; Vera Cavalcanti Araujo
Journal:  Virchows Arch       Date:  2013-06-05       Impact factor: 4.064

6.  Mitochondrial redox signalling at a glance.

Authors:  Yvonne Collins; Edward T Chouchani; Andrew M James; Katja E Menger; Helena M Cochemé; Michael P Murphy
Journal:  J Cell Sci       Date:  2012-02-15       Impact factor: 5.285

7.  Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes.

Authors:  Ya-Jun Li; Wen-Qi Jiang; Hui-Lan Rao; Jia-Jia Huang; Yi Xia; Hui-Qiang Huang; Tong-Yu Lin; Zhong-Jun Xia; Su Li; Zhi-Ming Li
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

8.  Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.

Authors:  Tiantian He; Agata Banach-Latapy; Laurence Vernis; Michèle Dardalhon; Roland Chanet; Meng-Er Huang
Journal:  Carcinogenesis       Date:  2012-12-13       Impact factor: 4.741

9.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

10.  Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.

Authors:  Daisuke Kubota; Kenta Mukaihara; Akihiko Yoshida; Hitoshi Tsuda; Akira Kawai; Tadashi Kondo
Journal:  J Proteomics       Date:  2013-08-02       Impact factor: 4.044

View more
  1 in total

Review 1.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.